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As the scope of international travel expands, an
increasing number of travelers are coming into contact with
helminthic parasites rarely seen outside the tropics. As a
result, the occurrence of Gnathostoma spinigerum infection
leading to the clinical syndrome gnathostomiasis is increas-
ing.  In areas where Gnathostoma is not endemic, few cli-
nicians are familiar with this disease. To highlight this
underdiagnosed parasitic infection, we describe a case
series of patients with gnathostomiasis who were treated
during a 12-month period at the Hospital for Tropical
Diseases, London.
The ease of international travel in the 21st century hasresulted in persons from Europe and other western
countries traveling to distant areas of the world and return-
ing with an increasing array of parasitic infections rarely
seen in more temperate zones. One example is infection
with Gnathostoma spinigerum, which is acquired by eating
uncooked food infected with the larval third stage of the
helminth; such foods typically include fish, shrimp, crab,
crayfish, frog, or chicken. Previously, most disease related
to Gnathostoma was reported from Southeast Asia, partic-
ularly Thailand and Japan, because of the dietary habits of
those living there. In recent years, however, gnathostomia-
sis has become an increasing problem in Central and South
America, most notably in Mexico (perhaps related to con-
sumption of ceviche) (1,2). In cats and dogs, which serve
as important reservoirs of infection in regions where
Gnathostoma is endemic (3), the ingested third-stage larva
matures into the adult worm in approximately 6 months
(Figure 1). However, because the larva cannot mature into
the adult form in humans, the third-stage larva can only
wander within the body of the host; clinical symptoms of
gnathostomiasis then occur because of the inflammatory
reaction provoked by these migrating larvae (Figure 2). 
Traditionally the disease has been divided into cuta-
neous and visceral forms, depending on the site of larval
migration and subsequent symptoms. Another form of
gnathostomiasis, which is quite rare, includes the danger-
ous complication of central nervous system involvement
(4). This form is manifested by painful radiculopathy,
which can lead to paraplegia, sometimes following an
acute (eosinophilic) meningitic illness. 
We describe a series of patients in whom G. spinigerum
infection was diagnosed at the Hospital for Tropical
Diseases, London; they were treated over a 12-month peri-
od. Four illustrative case histories are described in detail.
This case series represents a small proportion of gnathos-
tomiasis patients receiving medical care in the United
Kingdom, in whom this uncommon parasitic infection is
mostly undiagnosed. 
Methods
The case notes of patients in whom gnathostomiasis
was diagnosed at the Hospital for Tropical Diseases were
reviewed retrospectively for clinical symptoms and confir-
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Figure 1. Life cycle of Gnathostoma spinigerum. Adapted from an
original illustration by Sylvia Paz Diaz Camacho; available from:
URL: http://www.dpd.cdc.gov/dpdx/ HTML/gnathostomiasis.htm
matory serologic results for the period April 1, 2000, to
March 31, 2001. Clinical and laboratory data gleaned from
case notes are described in the following sections.
Definitions
The definition of clinical Gnathostoma infection is:
1) a history of intermittent, migratory skin and subcuta-
neous swellings (localized or not localized) with or with-
out peripheral blood eosinophilia (eosinophil count >0.4 x
109/L), or 2) otherwise undiagnosed eosinophilia with non-
specific symptoms. Plausible epidemiologic risk is defined
as travel to an area in which gnathostomiasis had been
reported previously (i.e., Southeast Asia and Central and
South America). We did not impose a time limit on previ-
ous travel in our study. Positive Gnathostoma serologic
results were defined as the presence on immunoblot of the
specific 24-kDa band diagnostic of Gnathostoma infection
(5,6). All serologic testing for gnathostomiasis was per-
formed in the Department of Helminthology of the Faculty
of Tropical Medicine at Mahidol University in Bangkok,
Thailand. For patients at risk of Loa loa infection (because
of previous travel to regions in central or West Africa
where the infection is endemic), day-blood tests (samples
taken between 12:00–2:00 p.m.) were performed to check
for microfilaria and a filaria enzyme-linked immunosor-
bent assay was performed to exclude this diagnosis
(Calabar swellings, indicative of Loa loa infection, may
mimic gnathostomiasis). 
Results 
During the 12-month study period, we identified 16
patients who had clinical symptoms consistent with
Gnathostoma infection, a plausible epidemiologic risk,
and positive serologic results. Seven patients were referred
by their general practitioner (primary care physician) and
four by consultant physicians working elsewhere in
London. Median time from onset of symptoms to diagno-
sis was 12 months (range 3 weeks–5 years). A dietary his-
tory was recorded for three patients who reported eating
(among other things) raw fish and watercress (patient 1);
mutton, fish, and chicken in Bangladesh (patient 3); and
fish and a variety of crustacea from market stalls in
Southeast Asia (patient 13). Eosinophilia was noted in
seven patients and was usually modest, always declining
after treatment. Median erythrocyte sedimentation rate
(available for 12 patients, data not shown) was 10 (range
1–62). The countries visited most frequently by our 16
patients were India (n=4), Bangladesh (n=3), China (n=2),
and Thailand (n=2). Standard treatment during the period
of study was albendazole (400 mg twice a day for 21 days).
Three patients required a second course for recurrence of
symptoms and incomplete resolution of eosinophilia.
Case Histories
Detailed travel histories for these patients are described
in the Table. The following sections include a case history
for four patients; all of these patients had positive
Gnathostoma serologic results and responded to albenda-
zole therapy.
Case 1
A 26-year-old Asian woman, a resident of Hong Kong,
was referred to our hospital by her primary care physician.
She complained of the episodic appearance of “irritating”
lumps on her limbs. Nine months earlier, the first of these
lumps appeared on her right hand; since then, she had had
a similar lump on her left foot and left hand, each lasting a
few days and resolving spontaneously with no visible or
palpable sequelae. Nine years previously, she had noted a
lump rising near her left knee, which was followed 4 days
later by a similar lump on her right thigh; both lumps had
resolved spontaneously. All of the lumps were subcuta-
neous and estimated at 3–6 cm in diameter. A positive
rheumatoid factor and anti-nuclear antibody >1:1,280 were
noted. Her diet frequently included raw fish.
Case 2
A 37-year-old woman from Bangladesh reported a 3-
year history of intermittent swelling of the right forearm
and upper arm to the midbiceps area associated with pruri-
tus, myalgia, and arthralgia. The onset of her symptoms
had occurred while she was visiting Bangladesh, where
she had eaten mutton, fish, and chicken. An eosinophil
count of 4.37 x 109/L had prompted referral from a
rheumatology clinic to the Hospital for Tropical Diseases.
After a 21-day course of albendazole, her eosinophil count
decreased to 1.12 x 109/L; symptoms recurred several
months later. After treatment with a second course
of albendazole (400 mg twice a day for 21 days), her
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Figure 2. Third-stage larva of Gnathostoma spinigerum. A) whole
larva; B) head. (Reproduced with the permission of Pichart
Uparanukraw, Department of Parasitology, Faculty of Medicine,
Chiang Mai University, Thailand.)
symptoms resolved and her eosinophil count returned to
normal (0.25 x 109/L).
Case 3
A 49-year-old Caucasian woman complained of a 12-
month history of abdominal pain and symptoms suggest-
ing gastroesophageal reflux. She had traveled widely in
Southeast Asia 18 months earlier but denied eating crus-
tacea or non-kosher meat. Gastric biopsy at upper gastroin-
testinal endoscopy demonstrated eosinophilic gastritis
(peripheral blood eosinophil count of 0.95 x 109/L), a find-
ing that prompted serologic testing for Gnathostoma. Her
symptoms resolved with albendazole treatment.
Case 4
Pain developed in the left thigh of a 30-year-old man
while he was participating in the Eco-Challenge 2000 race
in Borneo. A 4x3-cm lump in his thigh was initially attrib-
uted to a muscular tear; when this lump persisted for 12
months, he was referred to the Hospital for Tropical
Diseases. Magnetic resonance imaging of the thigh (Figure
3) showed a lobulated lesion in the vastus lateralis muscle
surrounded by edema. Serologic results were positive for
Gnathostoma. Treatment with albendazole substantially
reduced the size and firmness of the lesion but did not
completely resolve it.
Discussion
This series is the first reported set of travelers with
gnathostomiasis. Patterns of international travel suggest
that this condition may be seen more often in travelers and
immigrants from regions in which the disease is endemic.
Moreover, the widening geographic distribution of the
infection and increasingly adventurous eating habits of
visitors to such regions are likely to contribute to an
increase in incidence. 
In our patients, the median time from onset of symp-
toms to diagnosis was 12 months, which reflects both the
intermittent, episodic nature of the symptoms and the
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Table. Background information on patients in whom Gnathostoma infection was identified, April 1, 2000, to March 31, 2001, Hospital 
for Tropical Diseases, Londona 
Patient 
no. Age Referral source Travel history 




1c 26 GP China, South Korea, Canada, Hong Kong, Tunisia 0.10 9 mo 
2 26 General physician Bangladesh, Italy 2.20 6 mo 
3c 37 Rheumatologist Bangladesh 4.37 3 y 
4 28 HTD walk-in Japan, Cuba 0.17 2 mo 
5 35 GP India, Sri Lanka NA 3 y 
6 34 HTD walk-in South Africa, New Zealand, Jakarta, Singapore 0.80 3 mo 
7 49 Dermatologist India, Thailand 0.1 13 mo 
8 51 GP Sri Lanka, Brazil, Cambodia 0.08 2 y 
9 26 Rheumatologist India 1.33 3 y 
10 27 GP Bangladesh 1.10 5 y 
11 23 GP SE Asia, Australia 0.00 4 mo 
12 25 self Japan, SE Asia, USA, Canada 0.11 13 mo 
13 24 HTD walk-in SE Asia, India, China 0.96 3 wk 
14c 49 Gastroenterologist Far East, Caribbean, USA 0.95 12 mo 
15 57 GP Vietnam, Thailand 0.26 6 mo 
16c 30 GP Borneo, Belize, Ecuador, Peru, Australia 0.11 12 mo 
aGP, general practitioner; HTD walk-in, Hospital for Tropical Diseases emergency walk-in clinic; NA, not available. 
bNormal range 0–0.4 x 109/l. 
cDenotes case history in text. 
 
Figure 3. Magnetic resonance image of thigh with Gnathostoma
larva (case 4).
obscurity of the diagnosis. We do not have data on the time
to diagnosis after medical attention was sought, but anec-
dotally we often and understandably find a considerable
delay.
The key to diagnosis of gnathostomiasis is recognition
of the highly suggestive clinical history; cases 1 and 2 are
the most typical. Once the disease is diagnosed, manage-
ment is straightforward, but the rarity of the condition in
areas in which the condition is not endemic might lead to
the diagnosis’ being overlooked. The unusual symptoms,
combined with the usual absence of physical signs
between episodes, may lead to discounting of the symp-
toms and erroneous reassurance of the patient by clinicians
unfamiliar with gnathostomiasis. Patients may be referred
to rheumatology, dermatology, or general medical clinics;
the absence of eosinophilia may also prevent due consider-
ation of possible parasitic causes. Eosinophilia was present
in only seven of our patients and thus cannot be considered
as a screening tool. However, as a marker of treatment
response in those with eosinophilia at baseline, this inves-
tigation was proven useful; for the three patients requiring
a second course of albendazole, residual eosinophilia pre-
ceded symptom relapse. 
Because of little information about dietary intake, we
cannot comment on the sources of infection in our patients.
More detailed dietary histories are now recorded routinely
at the Hospital for Tropical Diseases, but the notorious
inaccuracy of verbal dietary histories and the broad range
of potential culprits eaten by many travelers suggest that,
for identifying the source in humans, dietary history is usu-
ally of limited value.
A number of serologic tests are available for the diag-
nosis of gnathostomiasis. Our testing is performed at
Mahidol University in Thailand by using an immunoblot to
detect the specific 24-kDa band considered diagnostic of
Gnathostoma infection. In that laboratory, for the four par-
asite-confirmed cases of Gnathostoma, the immunoblot
was 100% sensitive, and antibodies of 15 parasitic diseases
and one mixed infection were not cross-reactive, except
for 1 of 13 samples from patients with paragonimiasis
which gave a weak reaction against this antigen (5).
Antibodies from 16 patients with confirmed cases of
Gnathostoma were consistently reactive with this 24-kDa
antigen. Cross-reactivity was not found in a further exten-
sive study of parasitic and nonparasitic diseases (6). 
The reported efficacy of albendazole in the treatment of
gnathostomiasis is >90% (7,8), and similar success has
been reported for ivermectin (8). Three of our patients
required a second course of treatment. The episodic nature
of this condition means that an initial determination is dif-
ficult as to whether cure has been effected, but the resolu-
tion of eosinophilia and lack of symptom recurrence with-
in 12 months were taken as presumptive evidence of cure.
Although we used a second course of albendazole for
retreatment, ivermectin has also been used successfully (9). 
A diagnosis of gnathostomiasis should be considered
for patients with a history of transient, migratory cutaneous
or subcutaneous swellings, or nonspecific gastrointestinal
symptoms for which a potential epidemiologic exposure is
identified. Management of the disease thereafter is usually
relatively straightforward, although more than one course
of treatment may be required to effect a cure.
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